Research institution
Dana-Farber Cancer Institute Clinical Trials
Studies where Dana-Farber Cancer Institute is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 122Lymphoma, Primary Central Nervous System Lymphoma
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
This research study is studying if the investigational drug, Pembrolizumab, in combination with chemotherapy helps primary central nervous system lymphoma with acceptable side effects.
- Trial name
- NCT06475235
- Testing
- Pembrolizumab, Methotrexate, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Primary Central Nervous System Lymphoma, Recurrent Cancer
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL).
- Conditions
- Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
- Trial name
- NCT04421560
- Testing
- Ibrutinib, Pembrolizumab, Rituximab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dana-Farber Cancer Institute
Salivary Gland Cancer, Advanced Salivary Gland Carcinoma
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the study drug involved in this study is: -Ivonescimab (a type of antibody)
- Conditions
- Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic Carcinoma
- Trial name
- I-MAC (NCT06805617)
- Testing
- Ivonescimab
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Dana-Farber Cancer Institute
Non Small Cell Lung Cancer, Small Cell Lung Carcinoma
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
- Conditions
- Non Small Cell Lung Cancer, Small Cell Lung Carcinoma, NUT Carcinoma
- Trial name
- NCT05265429
- Testing
- Data and Specimen Collection
- Where
- 4 sites in United States
- Volunteers
- 500 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody)…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
- Trial name
- NCT06239220
- Testing
- PD-L1 t-haNK, Cetuximab, NAI
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC)
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as "flu shot") into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery.
- Conditions
- Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
- Trial name
- NCT06664151
- Testing
- Fluzone Trivalent
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Endometrial Cancer, Recurrent Endometrial Cancer
ALPINE: Maintenance Letrozole/Abemaciclib
The purpose of this research study is to see if the study drugs abemaciclib and letrozole are effective and safe for participants with estrogen-receptor positive (ER+), mismatch repair proficient, tumor protein p53 (TP53)…
- Conditions
- Endometrial Cancer, Recurrent Endometrial Cancer, TP53
- Trial name
- NCT06366347
- Testing
- Abemaciclib, Letrozole, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Non-Hodgkin's Lymphoma, Hodgkin's Disease
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different…
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Disease, Leukemia, Lymphocytic, Chronic, Lymphoproliferative Disorders
- Trial name
- NCT00131014
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia
Understanding Chronic Lymphocytic Leukemia
The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.
- Trial name
- NCT04028531
- Where
- United States
- Volunteers
- 2,750 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Cancer, Pain
Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing
The purpose of the study is to evaluate if the smartphone app, I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), helps participants with cancer pain manage symptoms and keep track of medications.
- Trial name
- NCT06117709
- Testing
- I-STAMP
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Dana-Farber Cancer Institute
Completed, with results posted
All –Cancer, Quality of Life
The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
Multi-Site Randomized Controlled Trial testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults with Advanced Cancer
- Conditions
- Cancer, Quality of Life, Anxiety, Depression
- Trial name
- PRISM-AC (NCT03668223)
- Testing
- Promoting Resilience in Stress Management (PRISM)
- Where
- 5 sites in United States
- Volunteers
- 269 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer Prevention, Weight Loss
PROFAST Intervention in Precursor Multiple Myeloma
This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM)…
- Conditions
- Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS
- Trial name
- PROFAST (NCT05565638)
- Testing
- Prolonged Fasting Intervention, EDUCATION CONTROL
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.
- Trial name
- NCT03414684
- Testing
- Carboplatin, Nivolumab
- Where
- 10 sites in United States
- Volunteers
- 78 people
- Sponsor
- Dana-Farber Cancer Institute
Thyroid Cancer
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Since thyroid cancer becomes refractory to radioactive iodine, treatment options are very limited. Tyrosine kinase inhibitors such as sorafenib have recently shown promise.
- Trial name
- NCT00936858
- Testing
- RAD001
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute
Thyroid Cancer
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
This research study is studying a targeted therapy as a possible treatment for thyroid cancer. A targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells…
- Trial name
- NCT02657551
- Testing
- Regorafenib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dana-Farber Cancer Institute